PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
19615464-4	2009	The proteins were active with various phosphatidylcholines (PCs) and phosphatidylethanolamines (PEs), and for most of substrates the PLA(1) activity was much higher than the PLA(2) activity.	Phosphatidylcholines	38-58	POU class 2 homeobox 3	Homo sapiens	133-139
24368210-8	2014	One more interesting finding is that human pancreatic lipase related protein 2 could hydrolyze phospholipids through its PLA1 and PLA2 activities.	Phospholipids	95-108	POU class 2 homeobox 3	Homo sapiens	121-125
24187982-8	2013	The enamido complex 9 reacts via beta-carbon methylation to give the primary imino complex cis-[Re(PNP(tBu)-HN CC(Me)Ph)(CO)2]OTf 11.	enamido	4-11	POU class 2 homeobox 3	Homo sapiens	126-132
24187982-8	2013	The enamido complex 9 reacts via beta-carbon methylation to give the primary imino complex cis-[Re(PNP(tBu)-HN CC(Me)Ph)(CO)2]OTf 11.	Carbon	38-44	POU class 2 homeobox 3	Homo sapiens	126-132
24187982-8	2013	The enamido complex 9 reacts via beta-carbon methylation to give the primary imino complex cis-[Re(PNP(tBu)-HN CC(Me)Ph)(CO)2]OTf 11.	tert-Butyl Alcohol	103-106	POU class 2 homeobox 3	Homo sapiens	126-132
22382206-2	2012	The analogous reaction with trans-dppen or dppa [dppa = bis(diphenylphosphino)acetylene] affords the cyclic trinuclear [Au(3)(mu-trans-dppen)(3)]X(3) (X = OTf 11, PF(6)12) and tetranuclear [Au(4)(mu-dppa)(4)]X(4) (X = OTf 13, PF(6)14, ClO(4)15) gold complexes, respectively.	trans-dppen	28-39	POU class 2 homeobox 3	Homo sapiens	155-161
22382206-2	2012	The analogous reaction with trans-dppen or dppa [dppa = bis(diphenylphosphino)acetylene] affords the cyclic trinuclear [Au(3)(mu-trans-dppen)(3)]X(3) (X = OTf 11, PF(6)12) and tetranuclear [Au(4)(mu-dppa)(4)]X(4) (X = OTf 13, PF(6)14, ClO(4)15) gold complexes, respectively.	dppa	43-47	POU class 2 homeobox 3	Homo sapiens	155-161
22382206-2	2012	The analogous reaction with trans-dppen or dppa [dppa = bis(diphenylphosphino)acetylene] affords the cyclic trinuclear [Au(3)(mu-trans-dppen)(3)]X(3) (X = OTf 11, PF(6)12) and tetranuclear [Au(4)(mu-dppa)(4)]X(4) (X = OTf 13, PF(6)14, ClO(4)15) gold complexes, respectively.	dppa	49-53	POU class 2 homeobox 3	Homo sapiens	155-161
22382206-2	2012	The analogous reaction with trans-dppen or dppa [dppa = bis(diphenylphosphino)acetylene] affords the cyclic trinuclear [Au(3)(mu-trans-dppen)(3)]X(3) (X = OTf 11, PF(6)12) and tetranuclear [Au(4)(mu-dppa)(4)]X(4) (X = OTf 13, PF(6)14, ClO(4)15) gold complexes, respectively.	Bis(diphenylphosphino)acetylene	56-87	POU class 2 homeobox 3	Homo sapiens	155-161
22382206-2	2012	The analogous reaction with trans-dppen or dppa [dppa = bis(diphenylphosphino)acetylene] affords the cyclic trinuclear [Au(3)(mu-trans-dppen)(3)]X(3) (X = OTf 11, PF(6)12) and tetranuclear [Au(4)(mu-dppa)(4)]X(4) (X = OTf 13, PF(6)14, ClO(4)15) gold complexes, respectively.	cyclic trinuclear	101-118	POU class 2 homeobox 3	Homo sapiens	155-161
22382206-2	2012	The analogous reaction with trans-dppen or dppa [dppa = bis(diphenylphosphino)acetylene] affords the cyclic trinuclear [Au(3)(mu-trans-dppen)(3)]X(3) (X = OTf 11, PF(6)12) and tetranuclear [Au(4)(mu-dppa)(4)]X(4) (X = OTf 13, PF(6)14, ClO(4)15) gold complexes, respectively.	Gold	120-122	POU class 2 homeobox 3	Homo sapiens	155-161
22382206-2	2012	The analogous reaction with trans-dppen or dppa [dppa = bis(diphenylphosphino)acetylene] affords the cyclic trinuclear [Au(3)(mu-trans-dppen)(3)]X(3) (X = OTf 11, PF(6)12) and tetranuclear [Au(4)(mu-dppa)(4)]X(4) (X = OTf 13, PF(6)14, ClO(4)15) gold complexes, respectively.	mu-trans-dppen)	126-141	POU class 2 homeobox 3	Homo sapiens	155-161
22382206-2	2012	The analogous reaction with trans-dppen or dppa [dppa = bis(diphenylphosphino)acetylene] affords the cyclic trinuclear [Au(3)(mu-trans-dppen)(3)]X(3) (X = OTf 11, PF(6)12) and tetranuclear [Au(4)(mu-dppa)(4)]X(4) (X = OTf 13, PF(6)14, ClO(4)15) gold complexes, respectively.	pyrazofurin	163-165	POU class 2 homeobox 3	Homo sapiens	155-161
22382206-2	2012	The analogous reaction with trans-dppen or dppa [dppa = bis(diphenylphosphino)acetylene] affords the cyclic trinuclear [Au(3)(mu-trans-dppen)(3)]X(3) (X = OTf 11, PF(6)12) and tetranuclear [Au(4)(mu-dppa)(4)]X(4) (X = OTf 13, PF(6)14, ClO(4)15) gold complexes, respectively.	mu-dppa	196-203	POU class 2 homeobox 3	Homo sapiens	155-161
22382206-2	2012	The analogous reaction with trans-dppen or dppa [dppa = bis(diphenylphosphino)acetylene] affords the cyclic trinuclear [Au(3)(mu-trans-dppen)(3)]X(3) (X = OTf 11, PF(6)12) and tetranuclear [Au(4)(mu-dppa)(4)]X(4) (X = OTf 13, PF(6)14, ClO(4)15) gold complexes, respectively.	pyrazofurin	226-228	POU class 2 homeobox 3	Homo sapiens	155-161
22382206-2	2012	The analogous reaction with trans-dppen or dppa [dppa = bis(diphenylphosphino)acetylene] affords the cyclic trinuclear [Au(3)(mu-trans-dppen)(3)]X(3) (X = OTf 11, PF(6)12) and tetranuclear [Au(4)(mu-dppa)(4)]X(4) (X = OTf 13, PF(6)14, ClO(4)15) gold complexes, respectively.	clo	235-238	POU class 2 homeobox 3	Homo sapiens	155-161
20739877-3	2010	To evaluate the association between glycoprotein IIIa PlA1/PlA2 polymorphism and 1-year cardiovascular events occurrence in aspirin-treated patients with stable coronary artery disease.	Aspirin	124-131	POU class 2 homeobox 3	Homo sapiens	54-58
20537646-8	2010	Independent of other dietary factors, alcohol consumption was inversely associated with levels of pan-leukocyte marker (CD45), P-selectin (CD62P) on PLA1 and on PLA2 platelets, and platelet-monocyte, platelet-granulocyte, and platelet-lymphocyte aggregates.	Alcohols	38-45	POU class 2 homeobox 3	Homo sapiens	149-153
20138334-9	2010	HPR patients with inadequate aspirin inhibition were significantly more often homozygous PlA1/A1 (65.4% vs. 47.7%, p=0.015).	Aspirin	29-36	POU class 2 homeobox 3	Homo sapiens	89-96
20138334-11	2010	CONCLUSION: In CAD patients receiving daily low dose of aspirin, there is a significant and independent association between the expression of GPIIIa PlA1 allele and the occurrence of persistent HPR detected with PFA-100.	Aspirin	56-63	POU class 2 homeobox 3	Homo sapiens	149-153
20138334-11	2010	CONCLUSION: In CAD patients receiving daily low dose of aspirin, there is a significant and independent association between the expression of GPIIIa PlA1 allele and the occurrence of persistent HPR detected with PFA-100.	Foscarnet	212-215	POU class 2 homeobox 3	Homo sapiens	149-153
20335986-4	2010	A variety of chemical and enzymatic routes have been reported in the literature for the synthesis of LPLs: the enzymatic transformation of natural glycerophospholipids (GPLs) using regiospecific enzymes such as phospholipases A1 (PLA1), A2 (PLA2) phospholipase D (PLD) and different lipases, the coupling of enzymatic processes with chemical transformations, the complete chemical synthesis of LPLs starting from glycerol or derivatives.	Glycerophospholipids	147-167	POU class 2 homeobox 3	Homo sapiens	230-234
20335986-4	2010	A variety of chemical and enzymatic routes have been reported in the literature for the synthesis of LPLs: the enzymatic transformation of natural glycerophospholipids (GPLs) using regiospecific enzymes such as phospholipases A1 (PLA1), A2 (PLA2) phospholipase D (PLD) and different lipases, the coupling of enzymatic processes with chemical transformations, the complete chemical synthesis of LPLs starting from glycerol or derivatives.	Lysophospholipids	101-105	POU class 2 homeobox 3	Homo sapiens	230-234
19615464-4	2009	The proteins were active with various phosphatidylcholines (PCs) and phosphatidylethanolamines (PEs), and for most of substrates the PLA(1) activity was much higher than the PLA(2) activity.	Phosphatidylcholines	60-63	POU class 2 homeobox 3	Homo sapiens	133-139
19615464-4	2009	The proteins were active with various phosphatidylcholines (PCs) and phosphatidylethanolamines (PEs), and for most of substrates the PLA(1) activity was much higher than the PLA(2) activity.	Phosphatidylethanolamines	69-94	POU class 2 homeobox 3	Homo sapiens	133-139
19615464-4	2009	The proteins were active with various phosphatidylcholines (PCs) and phosphatidylethanolamines (PEs), and for most of substrates the PLA(1) activity was much higher than the PLA(2) activity.	Phosphatidylethanolamines	96-99	POU class 2 homeobox 3	Homo sapiens	133-139
18429969-6	2008	The PlA1/A2 variant was significantly associated with aspirin resistance when measured in healthy subjects [odds ratio (OR) 2.36, 95% confidence interval (CI) 1.24, 4.49; P = 0.009].	Aspirin	54-61	POU class 2 homeobox 3	Homo sapiens	4-11
18996473-2	2009	LPA can be generated intracellularly and extracellularly through multiple synthetic pathways by action of various enzymes, such as phospholipase A(1/2) (PLA(1/2)), phospholipase D (PLD), acylglycerol kinase (AGK), and lysophospholipase D (lysoPLD).	lysophosphatidic acid	0-3	POU class 2 homeobox 3	Homo sapiens	153-161
18429969-8	2008	Moreover, the observed effect of PlA1/A2 genotype varied depending on the methodology used for determining aspirin sensitivity/resistance.	Aspirin	107-114	POU class 2 homeobox 3	Homo sapiens	33-37
18429969-10	2008	CONCLUSIONS: Our data support a genetic association between the PlA1/A2 molecular variant and aspirin resistance in healthy subjects, with the effect diminishing in the presence of cardiovascular disease.	Aspirin	94-101	POU class 2 homeobox 3	Homo sapiens	64-71
16607278-4	2006	Bisulfite sequencing analysis revealed that methylation of specific CpG sites (-287 to -70 bp) correlated with POU2F3 expression, which could be reactivated with a demethylating agent.	hydrogen sulfite	0-9	POU class 2 homeobox 3	Homo sapiens	111-117
27263955-9	2007	In comparison with wild types, platelets carrying the PlA1/A2 genotypes showed hyperaggregation measured in whole blood and induced by ristocetin (p< 0.05).	Ristocetin	135-145	POU class 2 homeobox 3	Homo sapiens	54-58
27263955-11	2007	According to mean fluorescence intensity with ADP induction, an increased expression of CD61+, CD61+/CD41+ and CD62P+ in PlA1/A2 platelets were detected as compared to the group carrying the wild type (p< 0.0001, p= 0.006, p= 0.0001), respectively.	Adenosine Diphosphate	46-49	POU class 2 homeobox 3	Homo sapiens	121-125
17954239-3	2007	In many studies, radiolabeled phospholipid substrates have been used to measure PLA(1) activity.	Phospholipids	30-42	POU class 2 homeobox 3	Homo sapiens	80-86
16607278-5	2006	Combined bisulfite restriction analysis revealed aberrant methylation of the POU2F3 promoter in 18 of 46 (39%) cervical tumors but never in normal epithelium.	hydrogen sulfite	9-18	POU class 2 homeobox 3	Homo sapiens	77-83
16458133-9	2006	With collagen as the agonist, platelets from PlA1/A2 donors were markedly and significantly less inhibited by ASA (p = 0.005).	Aspirin	110-113	POU class 2 homeobox 3	Homo sapiens	45-52
16824843-0	2006	Estradiol increases platelet aggregation in Pl(A1/A1) individuals.	Estradiol	0-9	POU class 2 homeobox 3	Homo sapiens	44-52
16154027-5	2005	The GPIIIa PLA1/PLA2 polymorphism has been associated with clopidogrel and orbofiban platelet response.	Clopidogrel	59-70	POU class 2 homeobox 3	Homo sapiens	11-15
16154027-5	2005	The GPIIIa PLA1/PLA2 polymorphism has been associated with clopidogrel and orbofiban platelet response.	orbofiban	75-84	POU class 2 homeobox 3	Homo sapiens	11-15
12573364-10	2002	PAF-AH equally can also hydrolyze short-chain diacylglycerols, triacylglycerols, and acetylated alkanols, and displays a PLA(1) activity.	Diglycerides	46-61	POU class 2 homeobox 3	Homo sapiens	121-127
15849372-9	2005	The paper focuses on the association between Pl(A1/A2) polymorphism and sensitivity (or resistance) to aspirin and the inhibitory efficacy of GPIIb-IIIa antagonists.	Aspirin	103-110	POU class 2 homeobox 3	Homo sapiens	45-53
15077167-3	2004	From HeLa/Tet-On, a clone that can be induced to make hSkn-1a by doxycycline (HeLa/hSkn-1a) was prepared and characterized.	tetramethylenedisulfotetramine	10-13	POU class 2 homeobox 3	Homo sapiens	54-61
15077167-3	2004	From HeLa/Tet-On, a clone that can be induced to make hSkn-1a by doxycycline (HeLa/hSkn-1a) was prepared and characterized.	tetramethylenedisulfotetramine	10-13	POU class 2 homeobox 3	Homo sapiens	83-90
15077167-3	2004	From HeLa/Tet-On, a clone that can be induced to make hSkn-1a by doxycycline (HeLa/hSkn-1a) was prepared and characterized.	Doxycycline	65-76	POU class 2 homeobox 3	Homo sapiens	54-61
15077167-3	2004	From HeLa/Tet-On, a clone that can be induced to make hSkn-1a by doxycycline (HeLa/hSkn-1a) was prepared and characterized.	Doxycycline	65-76	POU class 2 homeobox 3	Homo sapiens	83-90
15077167-5	2004	While maintained for several days in the presence of doxycycline, the HeLa/hSkn-1a cells showed a slightly prolonged time of population doubling, the occasional appearance of flat cells with lowered DNA synthesis, and a low level of apoptotic DNA fragmentation.	Doxycycline	53-64	POU class 2 homeobox 3	Homo sapiens	75-82
15990752-10	2005	The Pl A1,A1 allele of glycoprotein IIIa was present in 36 subjects (83.7.%) and the Pl A1,A2 allele was present in 7 subjects (16.2.%) in the aspirin-resistant patients group.	Aspirin	143-150	POU class 2 homeobox 3	Homo sapiens	85-90
15990752-11	2005	The Pl A1,A1 allele of glycoprotein IIIa was present in 37 subjects (72.5%) and the Pl A1,A2 allele was present in 14 subjects (27.5%) in the aspirin-sensitive patients group ( P = .195).	Aspirin	142-149	POU class 2 homeobox 3	Homo sapiens	4-9
15990752-11	2005	The Pl A1,A1 allele of glycoprotein IIIa was present in 37 subjects (72.5%) and the Pl A1,A2 allele was present in 14 subjects (27.5%) in the aspirin-sensitive patients group ( P = .195).	Aspirin	142-149	POU class 2 homeobox 3	Homo sapiens	84-89
12963729-2	2003	The sequence of mPAPLA1beta encodes a 460-amino acid protein containing a lipase domain with significant homology to the previously identified phosphatidic acid (PA)-selective PLA1, mPA-PLA1alpha.	Phosphatidic Acids	143-160	POU class 2 homeobox 3	Homo sapiens	19-23
12963729-4	2003	Both mPA-PLA1beta and mPA-PLA1alpha recombinant proteins exhibited PA-specific PLA1 activity and were vanadate-sensitive.	Phosphatidic Acids	6-8	POU class 2 homeobox 3	Homo sapiens	9-13
12963729-4	2003	Both mPA-PLA1beta and mPA-PLA1alpha recombinant proteins exhibited PA-specific PLA1 activity and were vanadate-sensitive.	Vanadates	102-110	POU class 2 homeobox 3	Homo sapiens	9-13
12963729-10	2003	We also found that the membrane-associated mPA-PLA1s were insoluble in solubilization by 1% Triton X-100 and were detected in Triton X-100-insoluble buoyant fractions of sucrose gradients.	Octoxynol	92-104	POU class 2 homeobox 3	Homo sapiens	47-51
12963729-10	2003	We also found that the membrane-associated mPA-PLA1s were insoluble in solubilization by 1% Triton X-100 and were detected in Triton X-100-insoluble buoyant fractions of sucrose gradients.	Octoxynol	126-138	POU class 2 homeobox 3	Homo sapiens	47-51
12963729-10	2003	We also found that the membrane-associated mPA-PLA1s were insoluble in solubilization by 1% Triton X-100 and were detected in Triton X-100-insoluble buoyant fractions of sucrose gradients.	Sucrose	170-177	POU class 2 homeobox 3	Homo sapiens	47-51
13678940-0	2003	Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms.	Aspirin	32-39	POU class 2 homeobox 3	Homo sapiens	68-72
13678940-7	2003	Aspirin-resistant patients were significantly more often Pl(A1/A1) (86.2%; n = 25) than sensitive patients (59.4%; n = 41; p = 0.01).	Aspirin	0-7	POU class 2 homeobox 3	Homo sapiens	57-65
13678940-11	2003	CONCLUSIONS: Platelets homozygous for the Pl(A1) allele appear to be less sensitive to inhibitory action of low-dose aspirin.	Aspirin	117-124	POU class 2 homeobox 3	Homo sapiens	42-47
12573364-10	2002	PAF-AH equally can also hydrolyze short-chain diacylglycerols, triacylglycerols, and acetylated alkanols, and displays a PLA(1) activity.	Triglycerides	63-79	POU class 2 homeobox 3	Homo sapiens	121-127
12573364-10	2002	PAF-AH equally can also hydrolyze short-chain diacylglycerols, triacylglycerols, and acetylated alkanols, and displays a PLA(1) activity.	alkanols	96-104	POU class 2 homeobox 3	Homo sapiens	121-127
11054089-0	2000	Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa.	Aspirin	36-43	POU class 2 homeobox 3	Homo sapiens	52-56
11929870-12	2002	However, these lipids were converted to the corresponding lysolipids by released PLA1 and PLA2 activities.	lysolipids	58-68	POU class 2 homeobox 3	Homo sapiens	81-85
11447076-8	2001	The fibrinogen effect was genotype specific, however, in that the increase in platelet aggregability with higher fibrinogen was present for the Pl(A1/A1) genotype (P=0.0005 and P=0.03 for epinephrine- and ADP-induced aggregation, respectively) but not for the Pl(A2)-positive genotype (P>0.90).	Epinephrine	188-199	POU class 2 homeobox 3	Homo sapiens	144-152
11447076-8	2001	The fibrinogen effect was genotype specific, however, in that the increase in platelet aggregability with higher fibrinogen was present for the Pl(A1/A1) genotype (P=0.0005 and P=0.03 for epinephrine- and ADP-induced aggregation, respectively) but not for the Pl(A2)-positive genotype (P>0.90).	Adenosine Diphosphate	205-208	POU class 2 homeobox 3	Homo sapiens	144-152
11151063-8	2001	We found that physiologic concentrations of estrogen strongly and significantly inhibited the aggregation of PlA1/A2 platelets (P<.005 for epinephrine and P<.05 for adenosine diphosphate, induced aggregation, respectively) in both men and women.	Epinephrine	142-153	POU class 2 homeobox 3	Homo sapiens	109-113
11151063-8	2001	We found that physiologic concentrations of estrogen strongly and significantly inhibited the aggregation of PlA1/A2 platelets (P<.005 for epinephrine and P<.05 for adenosine diphosphate, induced aggregation, respectively) in both men and women.	Adenosine Diphosphate	171-192	POU class 2 homeobox 3	Homo sapiens	109-113
11545752-6	2001	Compared with the placebo group, pravastatin reduced the excess RR of coronary disease death and recurrent MI in the Pl(A1,A2) patient population by 31% (p = 0.06).	Pravastatin	33-44	POU class 2 homeobox 3	Homo sapiens	117-122
11545752-8	2001	Among the Pl(A1,A2) patients, pravastatin had little effect on the risk of recurrent events with the ACE II genotype, but reduced the adjusted RR from 1.42 (placebo) to 0.58 for ACE ID patients, and from 1.56 (placebo) to 0.83 for ACE DD.	Pravastatin	30-41	POU class 2 homeobox 3	Homo sapiens	10-15
11545752-9	2001	The Pl(A1,A2) genotype was associated with an excess of recurrent coronary events in patients after MI who did not receive pravastatin, and the ACE D allele added to this risk.	Pravastatin	123-134	POU class 2 homeobox 3	Homo sapiens	4-9
11054082-5	2000	Subjects with PlA1/A2 polymorphism or with Pl(A2/A2) polymorphism showed significantly lower platelet responses as compared with Pl(A1/A1) subjects when either arachidonic acid or the thromboxane A(2) analogue, U46619, were used as agonists.	Arachidonic Acid	160-176	POU class 2 homeobox 3	Homo sapiens	14-18
11054082-5	2000	Subjects with PlA1/A2 polymorphism or with Pl(A2/A2) polymorphism showed significantly lower platelet responses as compared with Pl(A1/A1) subjects when either arachidonic acid or the thromboxane A(2) analogue, U46619, were used as agonists.	thromboxane a	184-197	POU class 2 homeobox 3	Homo sapiens	14-18
11054082-5	2000	Subjects with PlA1/A2 polymorphism or with Pl(A2/A2) polymorphism showed significantly lower platelet responses as compared with Pl(A1/A1) subjects when either arachidonic acid or the thromboxane A(2) analogue, U46619, were used as agonists.	15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid	211-217	POU class 2 homeobox 3	Homo sapiens	14-18
11054089-6	2000	Thus, BT both at baseline and after aspirin depends on the PlA1/A2 polymorphism of glycoprotein IIIa.	Aspirin	36-43	POU class 2 homeobox 3	Homo sapiens	59-63
10758736-1	1999	BACKGROUND: The PlA1/A2 polymorphism of the human platelet membrane glycoprotein IIIa gene cause T-->C transition in the exon ii (position 1565) resulting in the leucine-->proline substitution in amino-acid sequence.	Proline	178-185	POU class 2 homeobox 3	Homo sapiens	16-20
10704169-7	2000	Pl(A1,A2) platelets were more sensitive to inhibition of aggregation by pharmacologically relevant concentrations of aspirin and abciximab.	Aspirin	117-124	POU class 2 homeobox 3	Homo sapiens	0-5
10555781-3	1999	To do this, it is necessary to determine a "dilution factor" lambda, which estimates the contribution to the brain precursor acyl-CoA pool of fatty acids released from phospholipids through the action of PLA1 or PLA2.	Acyl Coenzyme A	125-133	POU class 2 homeobox 3	Homo sapiens	204-208
10555781-3	1999	To do this, it is necessary to determine a "dilution factor" lambda, which estimates the contribution to the brain precursor acyl-CoA pool of fatty acids released from phospholipids through the action of PLA1 or PLA2.	Fatty Acids	142-153	POU class 2 homeobox 3	Homo sapiens	204-208
10555781-3	1999	To do this, it is necessary to determine a "dilution factor" lambda, which estimates the contribution to the brain precursor acyl-CoA pool of fatty acids released from phospholipids through the action of PLA1 or PLA2.	Phospholipids	168-181	POU class 2 homeobox 3	Homo sapiens	204-208
10195947-10	1999	For epinephrine, the mean concentrations were 0.9 micromol/L (0.9 to 1.0) for homozygous PlA1, 0.7 mmol/L (0.7 to 0.9) for the heterozygous PlA1/PlA2, and 0.6 micromol/L (0.4 to 1.0) for homozygous PlA2 individuals, P=0.009.	Epinephrine	4-15	POU class 2 homeobox 3	Homo sapiens	89-93
10358058-2	1999	Transient expression of cPLA2-beta cDNA in COS cells results in an increase in calcium-dependent phospholipase A1 (PLA1) and PLA2 activities compared with vector-transfected cells.	carbonyl sulfide	43-46	POU class 2 homeobox 3	Homo sapiens	115-119
10358058-2	1999	Transient expression of cPLA2-beta cDNA in COS cells results in an increase in calcium-dependent phospholipase A1 (PLA1) and PLA2 activities compared with vector-transfected cells.	Calcium	79-86	POU class 2 homeobox 3	Homo sapiens	115-119
9805004-11	1998	This observation provides a potential explanation for the ability of GPLRP2 and DolmI PLA1 to hydrolyze polar lipids, such as phospholipids.	Phospholipids	126-139	POU class 2 homeobox 3	Homo sapiens	86-90
10072986-2	1997	The results showed: The gene frequency of PLA1 was 81.00% and 85.87% for Kob, 71.00% for Baka, 91.00% for Pena, 90.67% for Brb which provided the basis for further clinical application of HPA.	baka	89-93	POU class 2 homeobox 3	Homo sapiens	42-46
8928093-1	1996	The method described here results in simple visual analysis of 1, 2, or 3 ethidium bromide-stained bands corresponding to the PlA1, PlA2 or PlA1/A2 phenotypes, respectively.	Ethidium	74-90	POU class 2 homeobox 3	Homo sapiens	126-130
8896429-2	1996	The PLA1 epitope on platelet GPIIIa has a sulfhydryl-dependent conformation and is dependent on a leucine 33/proline33 polymorphism.	Sulfhydryl Compounds	42-52	POU class 2 homeobox 3	Homo sapiens	4-8
8896429-2	1996	The PLA1 epitope on platelet GPIIIa has a sulfhydryl-dependent conformation and is dependent on a leucine 33/proline33 polymorphism.	Leucine	98-105	POU class 2 homeobox 3	Homo sapiens	4-8
8896429-2	1996	The PLA1 epitope on platelet GPIIIa has a sulfhydryl-dependent conformation and is dependent on a leucine 33/proline33 polymorphism.	proline33	109-118	POU class 2 homeobox 3	Homo sapiens	4-8
8928093-1	1996	The method described here results in simple visual analysis of 1, 2, or 3 ethidium bromide-stained bands corresponding to the PlA1, PlA2 or PlA1/A2 phenotypes, respectively.	Ethidium	74-90	POU class 2 homeobox 3	Homo sapiens	140-144
7756638-5	1995	These findings provide evidence that the humoral response to the PlA1 antigen is (1) heterogenous, ie, the binding site on GPIIIa for human anti-PlA1 antibodies differs from one individual to another and (2) complex--although some anti-PlA1 alloantibodies bind to an epitope comprised solely of the amino-terminus of GPIIIa, others combine most efficiently with a more complex determinant that involves the cysteine-rich domain of GPIIIa.	Cysteine	407-415	POU class 2 homeobox 3	Homo sapiens	145-149
7756638-5	1995	These findings provide evidence that the humoral response to the PlA1 antigen is (1) heterogenous, ie, the binding site on GPIIIa for human anti-PlA1 antibodies differs from one individual to another and (2) complex--although some anti-PlA1 alloantibodies bind to an epitope comprised solely of the amino-terminus of GPIIIa, others combine most efficiently with a more complex determinant that involves the cysteine-rich domain of GPIIIa.	Cysteine	407-415	POU class 2 homeobox 3	Homo sapiens	145-149
7756638-0	1995	Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: evidence for heterogeneity in the humoral response.	Cysteine	19-27	POU class 2 homeobox 3	Homo sapiens	114-118
7756638-1	1995	To assess the potential contribution of the cysteine-rich domain of human platelet glycoprotein (GP) IIIa to the structure of the PlA1 epitope, we used site-directed mutagenesis to substitute alanines for cysteines at key positions potentially involved in PlA1 alloantigen formation.	Cysteine	44-52	POU class 2 homeobox 3	Homo sapiens	130-134
7756638-3	1995	Interestingly, of eight PlA1-specific antibodies tested, two recognized Ala435GPIIIa, two did not, and four bound to it less well than to wild-type (WT) GPIIIa.	ala435gpiiia	72-84	POU class 2 homeobox 3	Homo sapiens	24-28
7756638-4	1995	However, disruption of disulfide bonds located at or near the N-terminus of GPIIIa abolished the binding of all the anti-PlA1 alloantibodies tested.	Disulfides	23-32	POU class 2 homeobox 3	Homo sapiens	121-125
8140066-2	1993	Recently the use of allele-specific oligonucleotide probe typing for PlA (HPA-1) antigens has been described to determine the risk of second or subsequent fetuses in families where one infant had the diagnosis of anti-PlA1 (HPA-1a)-mediated NAIT (McFarland et al., 1991a).	Oligonucleotides	36-51	POU class 2 homeobox 3	Homo sapiens	218-222
7756638-5	1995	These findings provide evidence that the humoral response to the PlA1 antigen is (1) heterogenous, ie, the binding site on GPIIIa for human anti-PlA1 antibodies differs from one individual to another and (2) complex--although some anti-PlA1 alloantibodies bind to an epitope comprised solely of the amino-terminus of GPIIIa, others combine most efficiently with a more complex determinant that involves the cysteine-rich domain of GPIIIa.	Cysteine	407-415	POU class 2 homeobox 3	Homo sapiens	65-69
7993666-8	1994	We also found that exogenously added OAG underwent significant hydrolysis even in unstimulated platelets, but not in neutrophils, suggesting that exogenously added OAG may be readily accessible for diacylglycerol (DAG) lipase/PLA1 in platelets.	1-oleoyl-2-acetylglycerol	37-40	POU class 2 homeobox 3	Homo sapiens	226-230
7993666-8	1994	We also found that exogenously added OAG underwent significant hydrolysis even in unstimulated platelets, but not in neutrophils, suggesting that exogenously added OAG may be readily accessible for diacylglycerol (DAG) lipase/PLA1 in platelets.	1-oleoyl-2-acetylglycerol	164-167	POU class 2 homeobox 3	Homo sapiens	226-230
7993666-8	1994	We also found that exogenously added OAG underwent significant hydrolysis even in unstimulated platelets, but not in neutrophils, suggesting that exogenously added OAG may be readily accessible for diacylglycerol (DAG) lipase/PLA1 in platelets.	Diglycerides	198-212	POU class 2 homeobox 3	Homo sapiens	226-230
7519475-6	1994	Antigenicity of the PlA1 fusion protein in reduced glutathione increases with time; moreover, the addition of oxidized glutathione accelerates this process, presumably because of formation of the native disulfide bonds.	Glutathione	51-62	POU class 2 homeobox 3	Homo sapiens	20-24
7519475-6	1994	Antigenicity of the PlA1 fusion protein in reduced glutathione increases with time; moreover, the addition of oxidized glutathione accelerates this process, presumably because of formation of the native disulfide bonds.	Glutathione	119-130	POU class 2 homeobox 3	Homo sapiens	20-24
7519475-6	1994	Antigenicity of the PlA1 fusion protein in reduced glutathione increases with time; moreover, the addition of oxidized glutathione accelerates this process, presumably because of formation of the native disulfide bonds.	Disulfides	203-212	POU class 2 homeobox 3	Homo sapiens	20-24
1285806-2	1992	Chloroquine-treated platelet membranes generated the cleanest blots, giving end-point titres of 4000-16,000 for three different anti-PlA1 sera.	Chloroquine	0-11	POU class 2 homeobox 3	Homo sapiens	133-137
8485868-2	1993	On the basis of a position-specific fatty acid analysis of the natural substrate ("soybean lecithin") from a commercial PLA kit, serum activities of PLA1 could be clearly distinguished from those of PLA2, which is not possible in the usual measurements made with single-label radioactive substrates.	Fatty Acids	36-46	POU class 2 homeobox 3	Homo sapiens	149-153
8485868-2	1993	On the basis of a position-specific fatty acid analysis of the natural substrate ("soybean lecithin") from a commercial PLA kit, serum activities of PLA1 could be clearly distinguished from those of PLA2, which is not possible in the usual measurements made with single-label radioactive substrates.	Lecithins	91-99	POU class 2 homeobox 3	Homo sapiens	149-153
8485868-4	1993	Nevertheless, very low PLA1 activities (< or = 5 U/L, most likely due to heparin perfusion therapy) could also be detected by palmitic and stearic acid release from the sn-1 position, leading to small changes in fatty acid release patterns of sera with low PLA activities.	Heparin	76-83	POU class 2 homeobox 3	Homo sapiens	23-27
8485868-4	1993	Nevertheless, very low PLA1 activities (< or = 5 U/L, most likely due to heparin perfusion therapy) could also be detected by palmitic and stearic acid release from the sn-1 position, leading to small changes in fatty acid release patterns of sera with low PLA activities.	stearic acid	142-154	POU class 2 homeobox 3	Homo sapiens	23-27
8485868-4	1993	Nevertheless, very low PLA1 activities (< or = 5 U/L, most likely due to heparin perfusion therapy) could also be detected by palmitic and stearic acid release from the sn-1 position, leading to small changes in fatty acid release patterns of sera with low PLA activities.	Fatty Acids	215-225	POU class 2 homeobox 3	Homo sapiens	23-27
8485868-5	1993	Measurements with sera from heparin-treated volunteers demonstrated that heparin therapy may initially contribute as much as 22 U/L to increased PLA1 activities but is not important under prolonged therapy.	Heparin	28-35	POU class 2 homeobox 3	Homo sapiens	145-149
8485868-5	1993	Measurements with sera from heparin-treated volunteers demonstrated that heparin therapy may initially contribute as much as 22 U/L to increased PLA1 activities but is not important under prolonged therapy.	Heparin	73-80	POU class 2 homeobox 3	Homo sapiens	145-149
1926322-0	1991	Captopril-enhanced binding of PlA1 (HPA-1a) antibodies in posttransfusion purpura.	Captopril	0-9	POU class 2 homeobox 3	Homo sapiens	30-34
1370635-4	1992	Substitution of leucine33 (PlA1) with a proline33 (PlA2) by in vitro mutagenesis resulted in the loss of anti-PlA1 reactivity; however, this clone still reacted with anti-GPIIIa polyclonal antibodies.	leucine33	16-25	POU class 2 homeobox 3	Homo sapiens	27-31
1370635-4	1992	Substitution of leucine33 (PlA1) with a proline33 (PlA2) by in vitro mutagenesis resulted in the loss of anti-PlA1 reactivity; however, this clone still reacted with anti-GPIIIa polyclonal antibodies.	leucine33	16-25	POU class 2 homeobox 3	Homo sapiens	110-114
1370635-4	1992	Substitution of leucine33 (PlA1) with a proline33 (PlA2) by in vitro mutagenesis resulted in the loss of anti-PlA1 reactivity; however, this clone still reacted with anti-GPIIIa polyclonal antibodies.	proline33	40-49	POU class 2 homeobox 3	Homo sapiens	110-114
1383923-0	1992	Competitive binding of a monoclonal antibody SZ-21 with anti-PLA1 antibodies and its potential for clinical application.	sz-21	45-50	POU class 2 homeobox 3	Homo sapiens	61-65
1383923-2	1992	Conversely, the binding capacity of the platelets for SZ-21 was decreased in the presence of anti-PLA1 antibodies.	sz-21	54-59	POU class 2 homeobox 3	Homo sapiens	98-102
1383923-3	1992	In Western blots, the determinant for SZ-21 was present on GPIIIa from either PLA1 or PLA2 homozygotes, but SZ-21 did not affect the interaction of anti-Yukb alloantibodies with their target antigen on GPIIIa.	sz-21	38-43	POU class 2 homeobox 3	Homo sapiens	78-82
1383923-4	1992	These results suggest that SZ-21 reacts with an epitope on the GPIIIa molecule very close to but not identical with that for anti-PLA1.	sz-21	27-32	POU class 2 homeobox 3	Homo sapiens	130-134
1383923-5	1992	The existence of PLA1-reactive alloantibodies in serum could be demonstrated by their competitive effect on the binding of SZ-21.	sz-21	123-128	POU class 2 homeobox 3	Homo sapiens	17-21
1926322-1	1991	A case of posttransfusion purpura is reported in a 90-year-old patient whose PlA1 antibody (anti-HPA-1a) was found to bind better to HPA-1a in the presence of captopril, a drug the patient had taken.	Captopril	159-168	POU class 2 homeobox 3	Homo sapiens	77-81
2000640-4	1991	Exposure to 5 ppm NO2 for 48 hr resulted in a significant (p less than 0.01) increase in PLA1 activity in plasma membranes but not in mitochondrial or microsomal membranes of pulmonary artery endothelial cells, whereas PLA2 and DG lipase activities were comparable to controls in all membranes.	Nitrogen Dioxide	18-21	POU class 2 homeobox 3	Homo sapiens	89-93
2000640-5	1991	As a result of PLA1 activation, the total phospholipid content of the plasma membranes of NO2-exposed cells was significantly (p less than 0.01) reduced compared to controls.	Phospholipids	42-54	POU class 2 homeobox 3	Homo sapiens	15-19
2000640-5	1991	As a result of PLA1 activation, the total phospholipid content of the plasma membranes of NO2-exposed cells was significantly (p less than 0.01) reduced compared to controls.	Nitrogen Dioxide	90-93	POU class 2 homeobox 3	Homo sapiens	15-19
2000640-6	1991	Phosphatidylethanolamine (PE) content was reduced (p less than 0.05), whereas lyso-PE (LPE), a product of PLA1 hydrolysis of PE, as well as phosphatidylserine (PS) contents were increased (p less than 0.01 for both LPE and PS) in the plasma membranes of NO2-exposed cells.	lysophosphatidylethanolamine	78-85	POU class 2 homeobox 3	Homo sapiens	106-110
2000640-6	1991	Phosphatidylethanolamine (PE) content was reduced (p less than 0.05), whereas lyso-PE (LPE), a product of PLA1 hydrolysis of PE, as well as phosphatidylserine (PS) contents were increased (p less than 0.01 for both LPE and PS) in the plasma membranes of NO2-exposed cells.	lysophosphatidylethanolamine	87-90	POU class 2 homeobox 3	Homo sapiens	106-110
2000640-6	1991	Phosphatidylethanolamine (PE) content was reduced (p less than 0.05), whereas lyso-PE (LPE), a product of PLA1 hydrolysis of PE, as well as phosphatidylserine (PS) contents were increased (p less than 0.01 for both LPE and PS) in the plasma membranes of NO2-exposed cells.	phosphatidylethanolamine	83-85	POU class 2 homeobox 3	Homo sapiens	106-110
2000640-7	1991	Incorporation of exogenous PS into pulmonary artery endothelial cells mimicked the stimulatory effect of NO2 on PLA1 activity.	Phosphatidylserines	27-29	POU class 2 homeobox 3	Homo sapiens	112-116
2000640-7	1991	Incorporation of exogenous PS into pulmonary artery endothelial cells mimicked the stimulatory effect of NO2 on PLA1 activity.	Nitrogen Dioxide	105-108	POU class 2 homeobox 3	Homo sapiens	112-116
2000640-8	1991	These results demonstrate that NO2 specifically reacts with the plasma membrane component of pulmonary artery endothelial cells, causing specific activation of PLA1.	Nitrogen Dioxide	31-34	POU class 2 homeobox 3	Homo sapiens	160-164
2000640-9	1991	The NO2-induced increase of PS in the plasma membranes appears to be responsible for the specific activation of PLA1 in pulmonary artery endothelial cells.	Nitrogen Dioxide	4-7	POU class 2 homeobox 3	Homo sapiens	112-116
2000640-9	1991	The NO2-induced increase of PS in the plasma membranes appears to be responsible for the specific activation of PLA1 in pulmonary artery endothelial cells.	Phosphatidylserines	28-30	POU class 2 homeobox 3	Homo sapiens	112-116
2744637-3	1989	Initial identification of the platelet-specific antibodies was achieved by using chloroquine-treated PlA1(+) and PlA1(-) platelets.	Chloroquine	81-92	POU class 2 homeobox 3	Homo sapiens	101-105
34471538-8	2021	We genotyped aspirin-treated patients with T-ARMS-PCR for missense rs5918 (PlA1/A1) polymorphism of the ITGB3 gene.	Aspirin	13-20	POU class 2 homeobox 3	Homo sapiens	75-82
34502905-1	2021	In this study, four kinds of phospholipase A1-metal (Al/Co/Cu/Mn) hybrid nanostructures were prepared for enhancing the stability of the free PLA1.	Metals	46-51	POU class 2 homeobox 3	Homo sapiens	142-146
34502905-1	2021	In this study, four kinds of phospholipase A1-metal (Al/Co/Cu/Mn) hybrid nanostructures were prepared for enhancing the stability of the free PLA1.	Aluminum	53-55	POU class 2 homeobox 3	Homo sapiens	142-146
34502905-1	2021	In this study, four kinds of phospholipase A1-metal (Al/Co/Cu/Mn) hybrid nanostructures were prepared for enhancing the stability of the free PLA1.	Cobalt	56-58	POU class 2 homeobox 3	Homo sapiens	142-146
34502905-1	2021	In this study, four kinds of phospholipase A1-metal (Al/Co/Cu/Mn) hybrid nanostructures were prepared for enhancing the stability of the free PLA1.	Copper	59-61	POU class 2 homeobox 3	Homo sapiens	142-146
34502905-4	2021	After immobilization, the temperature tolerance of PLA1-metal hybrid nanostructures was enhanced.	Metals	56-61	POU class 2 homeobox 3	Homo sapiens	51-55
34502905-8	2021	In brief, using Co2+, Cu2+, Al3+, and Mn2+ as the hybridization materials for immobilization could improve the catalytic properties and stability of the free PLA1, suggesting a promising method for a wider application of PLA1 in many fields such as food, cosmetics, and the pharmaceutical industry.	Carbon Dioxide	16-20	POU class 2 homeobox 3	Homo sapiens	158-162
34502905-8	2021	In brief, using Co2+, Cu2+, Al3+, and Mn2+ as the hybridization materials for immobilization could improve the catalytic properties and stability of the free PLA1, suggesting a promising method for a wider application of PLA1 in many fields such as food, cosmetics, and the pharmaceutical industry.	Carbon Dioxide	16-20	POU class 2 homeobox 3	Homo sapiens	221-225
34502905-8	2021	In brief, using Co2+, Cu2+, Al3+, and Mn2+ as the hybridization materials for immobilization could improve the catalytic properties and stability of the free PLA1, suggesting a promising method for a wider application of PLA1 in many fields such as food, cosmetics, and the pharmaceutical industry.	cupric ion	22-26	POU class 2 homeobox 3	Homo sapiens	158-162
34502905-8	2021	In brief, using Co2+, Cu2+, Al3+, and Mn2+ as the hybridization materials for immobilization could improve the catalytic properties and stability of the free PLA1, suggesting a promising method for a wider application of PLA1 in many fields such as food, cosmetics, and the pharmaceutical industry.	cupric ion	22-26	POU class 2 homeobox 3	Homo sapiens	221-225
34502905-8	2021	In brief, using Co2+, Cu2+, Al3+, and Mn2+ as the hybridization materials for immobilization could improve the catalytic properties and stability of the free PLA1, suggesting a promising method for a wider application of PLA1 in many fields such as food, cosmetics, and the pharmaceutical industry.	ALUMINUM ION	28-32	POU class 2 homeobox 3	Homo sapiens	158-162
34502905-8	2021	In brief, using Co2+, Cu2+, Al3+, and Mn2+ as the hybridization materials for immobilization could improve the catalytic properties and stability of the free PLA1, suggesting a promising method for a wider application of PLA1 in many fields such as food, cosmetics, and the pharmaceutical industry.	ALUMINUM ION	28-32	POU class 2 homeobox 3	Homo sapiens	221-225
34502905-8	2021	In brief, using Co2+, Cu2+, Al3+, and Mn2+ as the hybridization materials for immobilization could improve the catalytic properties and stability of the free PLA1, suggesting a promising method for a wider application of PLA1 in many fields such as food, cosmetics, and the pharmaceutical industry.	Manganese(2+)	38-42	POU class 2 homeobox 3	Homo sapiens	158-162
34502905-8	2021	In brief, using Co2+, Cu2+, Al3+, and Mn2+ as the hybridization materials for immobilization could improve the catalytic properties and stability of the free PLA1, suggesting a promising method for a wider application of PLA1 in many fields such as food, cosmetics, and the pharmaceutical industry.	Manganese(2+)	38-42	POU class 2 homeobox 3	Homo sapiens	221-225
2565345-0	1989	The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing.	proline33	80-89	POU class 2 homeobox 3	Homo sapiens	33-37
2253331-1	1990	Phospholipases, a group of enzymes that catalyze the hydrolysis of membrane phospholipids, are classified according to the bond cleaved in a phospholipid into PLA1 (EC 3.1.1.3), PLA2 (EC 3.1.1.4), PLB (EC 3.1.1.5), PLC (EC 3.1.4.3), and PLD (EC 3.1.4.4).	Phospholipids	76-89	POU class 2 homeobox 3	Homo sapiens	159-163
2253331-1	1990	Phospholipases, a group of enzymes that catalyze the hydrolysis of membrane phospholipids, are classified according to the bond cleaved in a phospholipid into PLA1 (EC 3.1.1.3), PLA2 (EC 3.1.1.4), PLB (EC 3.1.1.5), PLC (EC 3.1.4.3), and PLD (EC 3.1.4.4).	Phospholipids	76-88	POU class 2 homeobox 3	Homo sapiens	159-163
34843683-0	2022	Selective measurement of NAPE-PLD activity via a PLA1/2-resistant fluorogenic N-acyl-phosphatidylethanolamine analog.	N-acylphosphatidylethanolamine	78-109	POU class 2 homeobox 3	Homo sapiens	49-55
34843683-5	2022	Recently, NAPE-PLD activity in cells has been assayed using the fluorogenic NAPE analogs PED-A1 and PED6, but these substrates also detect the activity of serine hydrolase-type lipases PLA1 and PLA2.	Serine	155-161	POU class 2 homeobox 3	Homo sapiens	185-189
3778827-0	1986	Alloantibody-induced platelet serotonin release is blocked by antibody to the platelet PLA1 antigen.	Serotonin	30-39	POU class 2 homeobox 3	Homo sapiens	87-91
3778827-4	1986	Anti-PlA1 at high concentration did not cause [14C]serotonin release and inhibited serotonin release by other alloantibodies to antigens on the platelet surface.	Serotonin	83-92	POU class 2 homeobox 3	Homo sapiens	5-9
6760957-2	1982	PEG precipitates obtained from the sera of subjects of known PlA1 and rhesus phenotype were resuspended in buffer and analyzed as representative of circulating immune complexes (CIC).	Polyethylene Glycols	0-3	POU class 2 homeobox 3	Homo sapiens	61-65
6330082-12	1984	In the presence of the four deoxy-nucleoside triphosphates, the preterminal protein, the adenovirus coded DNA binding protein, and an extract prepared from uninfected HeLa nuclei, the adenovirus DNA polymerase can elongate the preterminal-protein dCMP initiation complex formed on pLA1 DNA to full length (6.6 kilobase) DNA molecules.	deoxy-nucleoside triphosphates	28-58	POU class 2 homeobox 3	Homo sapiens	281-285
7199931-1	1982	An unusual patient with post-transfusion purpura is described who had a rapidly rising platelet count with high dose steroid treatment in the presence of an increasing anti-PlA1 antibody titre.	Steroids	117-124	POU class 2 homeobox 3	Homo sapiens	173-177
6238641-2	1984	Anti-PlA1 sera precipitated two bands, corresponding to platelet glycoproteins IIb and III, whether or not calcium was present during the procedure.	Calcium	107-114	POU class 2 homeobox 3	Homo sapiens	5-9
6760957-3	1982	The consumption of anti-PlA1 serum by CIC was determined by immunofluorescence and by inhibition of sodium 51chromate release from PlA1-positive target platelets.	cic	38-41	POU class 2 homeobox 3	Homo sapiens	24-28
6760957-3	1982	The consumption of anti-PlA1 serum by CIC was determined by immunofluorescence and by inhibition of sodium 51chromate release from PlA1-positive target platelets.	cic	38-41	POU class 2 homeobox 3	Homo sapiens	131-135
6760957-3	1982	The consumption of anti-PlA1 serum by CIC was determined by immunofluorescence and by inhibition of sodium 51chromate release from PlA1-positive target platelets.	sodium 51chromate	100-117	POU class 2 homeobox 3	Homo sapiens	24-28
6760957-3	1982	The consumption of anti-PlA1 serum by CIC was determined by immunofluorescence and by inhibition of sodium 51chromate release from PlA1-positive target platelets.	sodium 51chromate	100-117	POU class 2 homeobox 3	Homo sapiens	131-135
33219051-11	2020	They mediate amiloride-sensitive sodium taste and rely on Skn-1a for their generation and the CALHM ion channel for neurotransmitter release.	Amiloride	13-22	POU class 2 homeobox 3	Homo sapiens	58-64
33219051-0	2020	Sodium taste cells require Skn-1a for generation and share molecular features with sweet, umami, and bitter taste cells.	Sodium	0-6	POU class 2 homeobox 3	Homo sapiens	27-33
27553127-6	2016	Plasma nitrite concentration was significantly greater following BRJ versus PLA 1 h post supplementation, and remained higher in BRJ throughout the testing session (p < 0.01).	Nitrites	7-14	POU class 2 homeobox 3	Homo sapiens	76-81
33219051-3	2020	Here we demonstrate that sodium-taste cells distributed only in the anterior oral epithelia and involved in evoking salty taste also require Skn-1a for their generation.	Sodium	25-31	POU class 2 homeobox 3	Homo sapiens	141-147
32641497-1	2020	Recently, eicosanoid-lysophospholipids were identified as novel metabolites generated from the direct cyclooxygenase- or lipoxygenase-catalyzed oxidation of 2-arachidonoyl-lysophospholipids produced from either PLA1-mediated hydrolysis of diacyl arachidonoyl-phospholipids or through the cytochrome c-catalyzed oxidative hydrolysis of the vinyl ether linkage of arachidonoyl-plasmalogens.	eicosanoid-lysophospholipids	10-38	POU class 2 homeobox 3	Homo sapiens	211-215
32641497-1	2020	Recently, eicosanoid-lysophospholipids were identified as novel metabolites generated from the direct cyclooxygenase- or lipoxygenase-catalyzed oxidation of 2-arachidonoyl-lysophospholipids produced from either PLA1-mediated hydrolysis of diacyl arachidonoyl-phospholipids or through the cytochrome c-catalyzed oxidative hydrolysis of the vinyl ether linkage of arachidonoyl-plasmalogens.	2-arachidonoyl-lysophospholipids	157-189	POU class 2 homeobox 3	Homo sapiens	211-215
32641497-1	2020	Recently, eicosanoid-lysophospholipids were identified as novel metabolites generated from the direct cyclooxygenase- or lipoxygenase-catalyzed oxidation of 2-arachidonoyl-lysophospholipids produced from either PLA1-mediated hydrolysis of diacyl arachidonoyl-phospholipids or through the cytochrome c-catalyzed oxidative hydrolysis of the vinyl ether linkage of arachidonoyl-plasmalogens.	arachidonoyl	159-171	POU class 2 homeobox 3	Homo sapiens	211-215
30413435-2	2018	The human platelet-specific alloantigen 1a/1b (HPA-1a/1b; also known as PlA1/A2) alloantigen system of human platelet membrane glycoprotein (GP) IIIa is controlled by a Leu33Pro polymorphism and is responsible for ~80% of the cases of FNAIT.	leu33pro	169-177	POU class 2 homeobox 3	Homo sapiens	72-76
29371621-6	2018	Most importantly, based on the simulation observation that resveratrol has a high probability of forming hydrogen bonds with sn-1 and sn-2 ester groups, we discovered a new mechanism using experimental approach, in which resveratrol protects both sn-1 and sn-2 ester bonds of DPPC and distearoyl phosphatidylcholine (DSPC) from phospholipase A1 (PLA1) and phospholipase A2 (PLA2) cleavage.	Resveratrol	59-70	POU class 2 homeobox 3	Homo sapiens	346-350
29371621-6	2018	Most importantly, based on the simulation observation that resveratrol has a high probability of forming hydrogen bonds with sn-1 and sn-2 ester groups, we discovered a new mechanism using experimental approach, in which resveratrol protects both sn-1 and sn-2 ester bonds of DPPC and distearoyl phosphatidylcholine (DSPC) from phospholipase A1 (PLA1) and phospholipase A2 (PLA2) cleavage.	Hydrogen	105-113	POU class 2 homeobox 3	Homo sapiens	346-350
29371621-6	2018	Most importantly, based on the simulation observation that resveratrol has a high probability of forming hydrogen bonds with sn-1 and sn-2 ester groups, we discovered a new mechanism using experimental approach, in which resveratrol protects both sn-1 and sn-2 ester bonds of DPPC and distearoyl phosphatidylcholine (DSPC) from phospholipase A1 (PLA1) and phospholipase A2 (PLA2) cleavage.	SN-1	125-129	POU class 2 homeobox 3	Homo sapiens	346-350
29371621-6	2018	Most importantly, based on the simulation observation that resveratrol has a high probability of forming hydrogen bonds with sn-1 and sn-2 ester groups, we discovered a new mechanism using experimental approach, in which resveratrol protects both sn-1 and sn-2 ester bonds of DPPC and distearoyl phosphatidylcholine (DSPC) from phospholipase A1 (PLA1) and phospholipase A2 (PLA2) cleavage.	sn-2 ester	134-144	POU class 2 homeobox 3	Homo sapiens	346-350
29371621-6	2018	Most importantly, based on the simulation observation that resveratrol has a high probability of forming hydrogen bonds with sn-1 and sn-2 ester groups, we discovered a new mechanism using experimental approach, in which resveratrol protects both sn-1 and sn-2 ester bonds of DPPC and distearoyl phosphatidylcholine (DSPC) from phospholipase A1 (PLA1) and phospholipase A2 (PLA2) cleavage.	Resveratrol	221-232	POU class 2 homeobox 3	Homo sapiens	346-350
29371621-6	2018	Most importantly, based on the simulation observation that resveratrol has a high probability of forming hydrogen bonds with sn-1 and sn-2 ester groups, we discovered a new mechanism using experimental approach, in which resveratrol protects both sn-1 and sn-2 ester bonds of DPPC and distearoyl phosphatidylcholine (DSPC) from phospholipase A1 (PLA1) and phospholipase A2 (PLA2) cleavage.	sn-2 ester	256-266	POU class 2 homeobox 3	Homo sapiens	346-350
29371621-6	2018	Most importantly, based on the simulation observation that resveratrol has a high probability of forming hydrogen bonds with sn-1 and sn-2 ester groups, we discovered a new mechanism using experimental approach, in which resveratrol protects both sn-1 and sn-2 ester bonds of DPPC and distearoyl phosphatidylcholine (DSPC) from phospholipase A1 (PLA1) and phospholipase A2 (PLA2) cleavage.	1,2-Dipalmitoylphosphatidylcholine	276-280	POU class 2 homeobox 3	Homo sapiens	346-350
29371621-6	2018	Most importantly, based on the simulation observation that resveratrol has a high probability of forming hydrogen bonds with sn-1 and sn-2 ester groups, we discovered a new mechanism using experimental approach, in which resveratrol protects both sn-1 and sn-2 ester bonds of DPPC and distearoyl phosphatidylcholine (DSPC) from phospholipase A1 (PLA1) and phospholipase A2 (PLA2) cleavage.	1,2-distearoyllecithin	285-315	POU class 2 homeobox 3	Homo sapiens	346-350
29371621-6	2018	Most importantly, based on the simulation observation that resveratrol has a high probability of forming hydrogen bonds with sn-1 and sn-2 ester groups, we discovered a new mechanism using experimental approach, in which resveratrol protects both sn-1 and sn-2 ester bonds of DPPC and distearoyl phosphatidylcholine (DSPC) from phospholipase A1 (PLA1) and phospholipase A2 (PLA2) cleavage.	1,2-distearoyllecithin	317-321	POU class 2 homeobox 3	Homo sapiens	346-350
32266201-1	2020	PLA-1-Al2O3@LNCM synthesized using an efficient and facile plasma-enhanced method exhibits markedly improved capacity retention of 98.6% after 100 cycles, which is much larger than that of LNCM at 80% after 100 cycles.	lncm	12-16	POU class 2 homeobox 3	Homo sapiens	0-5
32266201-1	2020	PLA-1-Al2O3@LNCM synthesized using an efficient and facile plasma-enhanced method exhibits markedly improved capacity retention of 98.6% after 100 cycles, which is much larger than that of LNCM at 80% after 100 cycles.	lncm	189-193	POU class 2 homeobox 3	Homo sapiens	0-5
32266201-3	2020	More importantly, the rate performance of PLA-1-Al2O3@LNCM is improved because of the better electrolyte storage of the assembled hierarchical architecture of the Al2O3 coating layer according to unimpeded Li+ diffusion from electrode to electrolyte.	Aluminum Oxide	48-53	POU class 2 homeobox 3	Homo sapiens	42-47
32266201-4	2020	When cycling at 55 C, the PLA-1-Al2O3@LNCM shows 93.6% capacity retention after 100 cycles, which is greatly enhanced due to the uniform Al2O3 layer.	Aluminum Oxide	32-37	POU class 2 homeobox 3	Homo sapiens	26-31
32266201-4	2020	When cycling at 55 C, the PLA-1-Al2O3@LNCM shows 93.6% capacity retention after 100 cycles, which is greatly enhanced due to the uniform Al2O3 layer.	Aluminum Oxide	137-142	POU class 2 homeobox 3	Homo sapiens	26-31
31511539-1	2019	The aim of this study was to investigate the association among the PlA1/A2 gene polymorphism, laboratory aspirin resistance and adverse clinical outcomes in coronary artery disease (CAD) patients who were on aspirin maintainance therapy.	Aspirin	105-112	POU class 2 homeobox 3	Homo sapiens	67-71
31511539-1	2019	The aim of this study was to investigate the association among the PlA1/A2 gene polymorphism, laboratory aspirin resistance and adverse clinical outcomes in coronary artery disease (CAD) patients who were on aspirin maintainance therapy.	Aspirin	208-215	POU class 2 homeobox 3	Homo sapiens	67-71
31345709-1	2019	BACKGROUND: A multidrug-resistant co-lineage of Plasmodium falciparum malaria, named KEL1/PLA1, spread across Cambodia in 2008-13, causing high rates of treatment failure with the frontline combination therapy dihydroartemisinin-piperaquine.	Dihydroartemisinin mixture with piperaquine	210-240	POU class 2 homeobox 3	Homo sapiens	90-94
31002798-3	2019	Here, we show that the PNG-1/NGLY1 peptide:N-glycanase edits the sequence of SKN-1A protein by converting particular N-glycosylated asparagine residues to aspartic acid.	Nitrogen	24-25	POU class 2 homeobox 3	Homo sapiens	77-83
31002798-3	2019	Here, we show that the PNG-1/NGLY1 peptide:N-glycanase edits the sequence of SKN-1A protein by converting particular N-glycosylated asparagine residues to aspartic acid.	Asparagine	132-142	POU class 2 homeobox 3	Homo sapiens	77-83
31002798-3	2019	Here, we show that the PNG-1/NGLY1 peptide:N-glycanase edits the sequence of SKN-1A protein by converting particular N-glycosylated asparagine residues to aspartic acid.	Aspartic Acid	155-168	POU class 2 homeobox 3	Homo sapiens	77-83
31002798-4	2019	Genetically introducing aspartates at these N-glycosylation sites bypasses the requirement for PNG-1/NGLY1, showing that protein sequence editing rather than deglycosylation is key to SKN-1A function.	Aspartic Acid	24-34	POU class 2 homeobox 3	Homo sapiens	184-190
31002798-4	2019	Genetically introducing aspartates at these N-glycosylation sites bypasses the requirement for PNG-1/NGLY1, showing that protein sequence editing rather than deglycosylation is key to SKN-1A function.	Nitrogen	44-45	POU class 2 homeobox 3	Homo sapiens	184-190
29927323-1	2018	Intrahepatic cholestasis of pregnancy (ICP) is frequently accompanied by pruritus, whose etiology has been associated with an enhanced production of lysophosphatidic acid (LPA) by the combined action of phospholipase A1/A2 (PLA1/PLA2) and autotaxin (ATX).	lysophosphatidic acid	149-170	POU class 2 homeobox 3	Homo sapiens	224-228
29927323-1	2018	Intrahepatic cholestasis of pregnancy (ICP) is frequently accompanied by pruritus, whose etiology has been associated with an enhanced production of lysophosphatidic acid (LPA) by the combined action of phospholipase A1/A2 (PLA1/PLA2) and autotaxin (ATX).	lysophosphatidic acid	172-175	POU class 2 homeobox 3	Homo sapiens	224-228
26264906-9	2015	The genotype and allele frequencies of CYP2C19*2 and PLA1/A2 gene polymorphisms were significantly different between clopidogrel semi-responders and responders.	Clopidogrel	117-128	POU class 2 homeobox 3	Homo sapiens	53-57
26264906-13	2015	In an interim analysis on 72 Indian patients, a significant association was found between CYP2C19*2 and PLA1/A2 in clopidogrel semi-responders.	Clopidogrel	115-126	POU class 2 homeobox 3	Homo sapiens	104-108
26503625-2	2015	All HRASLS family members possess in vitro phospholipid metabolizing abilities including phospholipase A1/2 (PLA1/2) activities and O-acyltransferase activities for the remodeling of glycerophospholipid acyl chains, as well as N-acyltransferase activities for the production of N-acylphosphatidylethanolamines.	Glycerophospholipids	183-202	POU class 2 homeobox 3	Homo sapiens	109-115
25170810-1	2014	This paper presents the synthesis of structured phosphatidylcholine (PC) enriched with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) by transesterification of DHA/EPA-rich ethyl esters with PC using immobilized phospholipsase A1 (PLA1) in solvent-free medium.	Phosphatidylcholines	48-67	POU class 2 homeobox 3	Homo sapiens	243-247
25170810-1	2014	This paper presents the synthesis of structured phosphatidylcholine (PC) enriched with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) by transesterification of DHA/EPA-rich ethyl esters with PC using immobilized phospholipsase A1 (PLA1) in solvent-free medium.	Phosphatidylcholines	69-71	POU class 2 homeobox 3	Homo sapiens	243-247
25170810-1	2014	This paper presents the synthesis of structured phosphatidylcholine (PC) enriched with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) by transesterification of DHA/EPA-rich ethyl esters with PC using immobilized phospholipsase A1 (PLA1) in solvent-free medium.	Docosahexaenoic Acids	87-107	POU class 2 homeobox 3	Homo sapiens	243-247
25170810-1	2014	This paper presents the synthesis of structured phosphatidylcholine (PC) enriched with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) by transesterification of DHA/EPA-rich ethyl esters with PC using immobilized phospholipsase A1 (PLA1) in solvent-free medium.	Docosahexaenoic Acids	109-112	POU class 2 homeobox 3	Homo sapiens	243-247
25170810-1	2014	This paper presents the synthesis of structured phosphatidylcholine (PC) enriched with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) by transesterification of DHA/EPA-rich ethyl esters with PC using immobilized phospholipsase A1 (PLA1) in solvent-free medium.	Eicosapentaenoic Acid	118-139	POU class 2 homeobox 3	Homo sapiens	243-247
25170810-1	2014	This paper presents the synthesis of structured phosphatidylcholine (PC) enriched with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) by transesterification of DHA/EPA-rich ethyl esters with PC using immobilized phospholipsase A1 (PLA1) in solvent-free medium.	Eicosapentaenoic Acid	141-144	POU class 2 homeobox 3	Homo sapiens	243-247
25170810-1	2014	This paper presents the synthesis of structured phosphatidylcholine (PC) enriched with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) by transesterification of DHA/EPA-rich ethyl esters with PC using immobilized phospholipsase A1 (PLA1) in solvent-free medium.	Docosahexaenoic Acids	172-175	POU class 2 homeobox 3	Homo sapiens	243-247
25170810-1	2014	This paper presents the synthesis of structured phosphatidylcholine (PC) enriched with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) by transesterification of DHA/EPA-rich ethyl esters with PC using immobilized phospholipsase A1 (PLA1) in solvent-free medium.	Eicosapentaenoic Acid	176-179	POU class 2 homeobox 3	Homo sapiens	243-247
25170810-1	2014	This paper presents the synthesis of structured phosphatidylcholine (PC) enriched with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) by transesterification of DHA/EPA-rich ethyl esters with PC using immobilized phospholipsase A1 (PLA1) in solvent-free medium.	ethyl esters	185-197	POU class 2 homeobox 3	Homo sapiens	243-247
25170810-3	2014	Secondly, the immobilized PLA1 was used to catalyze transesterification of PC and DHA/EPA-rich ethyl esters.	Phosphatidylcholines	75-77	POU class 2 homeobox 3	Homo sapiens	26-30
25170810-3	2014	Secondly, the immobilized PLA1 was used to catalyze transesterification of PC and DHA/EPA-rich ethyl esters.	Docosahexaenoic Acids	82-85	POU class 2 homeobox 3	Homo sapiens	26-30
25170810-3	2014	Secondly, the immobilized PLA1 was used to catalyze transesterification of PC and DHA/EPA-rich ethyl esters.	Eicosapentaenoic Acid	86-89	POU class 2 homeobox 3	Homo sapiens	26-30
25170810-3	2014	Secondly, the immobilized PLA1 was used to catalyze transesterification of PC and DHA/EPA-rich ethyl esters.	ethyl esters	95-107	POU class 2 homeobox 3	Homo sapiens	26-30
25170810-4	2014	The maximal incorporation of DHA and EPA achieved was 30.7% for 24 h of reaction at 55  C using a substrate mass ratio (PC/ethyl esters) of 1:6, an immobilized PLA1 loading of 15% and water dosage of 1.25%.	Docosahexaenoic Acids	29-32	POU class 2 homeobox 3	Homo sapiens	160-164
25170810-4	2014	The maximal incorporation of DHA and EPA achieved was 30.7% for 24 h of reaction at 55  C using a substrate mass ratio (PC/ethyl esters) of 1:6, an immobilized PLA1 loading of 15% and water dosage of 1.25%.	Eicosapentaenoic Acid	37-40	POU class 2 homeobox 3	Homo sapiens	160-164